GH
DNLI icon

GAM Holding’s Denali Therapeutics DNLI Stock Holding History

GAM Holding’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,403
Closed -$247K – 236
2022
Q2 		$247K Hold
8,403
– – 0.02% 238
2022
Q1 		$270K Hold
8,403
– – 0.01% 291
2021
Q4 		$375K Hold
8,403
– – 0.02% 254
2021
Q3 		$424K Hold
8,403
– – 0.02% 246
2021
Q2 		$659K Buy
8,403
+3,903
+87% +$241K 0.03% 242
2021
Q1 		$257K Buy
+4,500
New +$301K 0.01% 291

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GAM Holding's DNLI Position: Q3 2022 in Review

GAM Holding sold out of Denali Therapeutics (DNLI) in Q3 2022, closing a stake of 8,403 shares — an estimated $247K sold.

GAM Holding first reported a position in DNLI in Q1 2021 and held it in 6 quarters. The position peaked at $659K in Q2 2021. 200 funds tracked by Wall St. Rank hold DNLI as of Q3 2022.

  • GAM Holding reported no remaining Denali Therapeutics position as of Q3 2022 after selling out during the quarter.
  • GAM Holding sold 8,403 Denali Therapeutics shares in Q3 2022, an estimated $247K.
  • GAM Holding first reported a position in Denali Therapeutics in Q1 2021 and held it in 6 quarters.
  • GAM Holding's Denali Therapeutics position peaked at $659K in Q2 2021.
  • 200 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2022.

Based on GAM Holding's 13F filing for Q3 2022, filed 19 Oct 2022.